ADC Sequencing in mTNBC: What Do You Do After Progression?

Multiple ADCs. Same payload. No prospective sequencing data.

Drs. Gradishar and Traina tackle one of the most difficult questions in mTNBC: how to sequence antibody–drug conjugates after progression. They break down why mechanism of action, cross-resistance, and toxicity profiles must guide treatment selection.

A candid discussion on what we know, what we don’t, and how patient tolerance shapes the real-world decision-making process.